Alzheimer’s disease and language impairments: Social intervention and medical treatment

Clinical Interventions in Aging

Volumn 10, Issue , 2015, Pages 1401-1408

  Klimova, Blanka ^a   Maresova, Petra ^a   Valis, Martin ^b   Hort, Jakub ^c,d   Kuca, Kamil ^a,b  

^a UNIVERSITY OF HRADEC KRALOVE   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

Alzheimer s disease; Caregivers; Clinical drugs; Language impairments; Social intervention; Strategies

Indexed keywords

DONEPEZIL; GALANTAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PLACEBO; RIVASTIGMINE; AMINO ACID RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR;

ALZHEIMER DISEASE; CAREGIVER; COMMUNICATION SKILL; DELUSION; DEMENTIA; HALLUCINATION; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; LANGUAGE DISABILITY; MILD COGNITIVE IMPAIRMENT; PSYCHOSIS; QUALITY OF LIFE; REVIEW; SHORT TERM MEMORY; SOCIAL INTERACTION; COMPLICATION; HUMAN RELATION; INTERPERSONAL COMMUNICATION; LANGUAGE DISORDERS; SOCIAL SUPPORT;

ALZHEIMER DISEASE; CAREGIVERS; CHOLINESTERASE INHIBITORS; COMMUNICATION; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; INTERPERSONAL RELATIONS; LANGUAGE DISORDERS; SOCIAL SUPPORT;

EID: 84940924047     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S89714     Document Type: Review

References (58)

1. OECD. Database Data: Population Development, Historical Data and Forecast; 2015 [cited June 9, 2015]. Available from: http://stats.oecd.org/#. Accessed April 20, 2015.
2. WHO. International Classification of Diseases (ICD); 1994 [cited June 9, 2015]. Available from: http://www.who.int/classifications/icd/en/Accessed April 20, 2015.
3. Stages of Alzheimer's. Alzheimer's Association; 2015 [cited June 9, 2015]. Available from: http://www.alz.org/alzheimers_disease_stages_of_alzheimers.asp. Accessed April 20, 2015.
4. Klímová B, Marešová P, Kuča K. Assistive technologies for language disorders in dementia [in review].
5. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):280-292.
6. Alzheimer's Association. Alzheimer's Disease Facts and Figures. Alzheimer's and Dementia; 2012 [cited June 9, 2015]. Available from: http://www.alz.org/downloads/Facts_Figures_2012.pdf. Accessed April 20, 2015.
7. Dementia of the Alzheimer's Type - Description of Stages. Website of Charles F. and Joanne Knight Alzheimer's Disease Research Center (Knight ADRC), Washington University School of Medicine in St Louis, Missouri, USA; 2003 [cited June 9, 2015]. Available from: http://knightadrc.wustl.edu/About_Us/PDFs/Stages_of_AD.pdf. Accessed April 20, 2015.
8. National Institute on Aging. Alzheimer's Disease. Unraveling 2 the Mystery. US; 2012 [cited Jun 9, 2015]. Available from: https://www.nia.nih.gov/sites/default/files/alzheimers_disease_unraveling_the_mystery.pdf. Accessed April 20, 2015.
9. Frederiks C, Hofmann MT, Reichard T. Advances in diagnosis and treatment of Alzheimer's disease. Hosp Physician. 2002;5:47-54.
10. Macoir J, Laforce R Jr, Monetta L, Wilson M. Language deficits in major forms of dementia and primary progressive aphasias: an update according to new diagnostic criteria. Geriatr Psychol Neuropsychiatr Vieil. 2014;12(2):199-208.
11. Shivanand P. Review on Alzheimer's disease: its cause, symptoms, and treatment at worldwide. Int J Appl Biol Pharm Technol. 2009;1(1):112-120.
12. Eliopoulos C, Carson VB, Varcarolis E. Cognitive disorders. Evolve Resources for Varcarolis' Foundations of Psychiatric Mental Health Nursing. St Louis, MO: Saunders Elsevier; 2006.
13. Pekkala S. Semantic Fluency in Mild and Moderate Alzheimer's Disease. Helsinki: Hakapaino Oy; 2004.
14. Orange JB, Colton-Hudson A. Enhancing communication in dementia of the Alzheimer's type. Top Geriatr Rehabil. 1998;14(2):56-75.
15. Savundranayagam ME, Ryan EB, Anas AP, Orange JB. Communication and dementia: staff perceptions of conversational strategies. Clin Gerontol. 2007;31(2):47-63.
16. Ferris SH, Farlow M. Language impairment in Alzheimer's disease and benefits of acetylcholinesterase inhibitors. Clin Interv Aging. 2013;8:1007-1014.
17. Maresova P, Klimova B, Kuca K. Alzheimer's disease: cost cuts call for novel drugs development and national strategy. Ceska A Slovenska Farmacie. 2015;64:25-30.
18. EC. European Initiative on Alzheimer's Disease and Other Dementias, Brussels; 2009 [cited June 9, 2015]. Available from: http://ec.europa.eu/health/ph_information/dissemination/documents/com2009_380_en.pdf. Accessed April 20, 2015.
19. Savundranayagam MY, Hummert ML, Montgomery RJ. Investigating the effects of communication problems on caregiver burden. J Gerontol B Psychol Sci Soc Sci. 2005;60(1):S48-S55.
20. Ripich DN. Functional communication with AD patients: a caregiver training program. Alzheimer Dis Assoc Disord. 1994;8(3):95-109.
21. Manenti R, Repetto C, Bentrovato S, Marcone A, Bates E, Cappa SF. The effects of ageing and Alzheimer's disease on semantic and gender priming. Brain. 2004;127(10):2299-2306.
22. Tang-Wai DF, Graham NL. Assessment of language function in dementia. Geriatr Aging. 2008;11:103-110.
23. Amieva H, Jacqmin-Gadda H, Orgogozo JM, et al. The 9-year cognitive decline before dementia of the Alzheimer type: a prospective population-based study. Brain. 2005;128:1093-1101.
24. Laws KR, Duncan A, Gale TM. "Normal' semantic-phonemic fluency discrepancy in Alzheimer's disease? A meta-analytic study. Cortex. 2010;46:595-601.
25. Stern Y, Albert S, Tang MX, Tsai WY. Rate of memory decline in AD is related to education and occupation: cognitive reserve? Neurology. 1999;53:1942-1957.
26. Fritsch T, McClendon MJ, Smyth KA, Ogrocki PK. Effects of educational attainment and occupational status on cognitive and functional decline in persons with Alzheimer-type dementia. Int J Geriatr Psychiatry. 2002;1:347-363.
27. Capitani E, Laiacona M, Basso A. Phonetically cued word-fluency, gender differences and aging: a reappraisal. Cortex. 1998;34:779-783.
28. Arrighi HM, Neumann PJ, Lieberburg IM, Townsend RJ. Lethality of Alzheimer disease and its impact on nursing home placement. Alzheimer Dis Assoc Disord. 2010;24(1):90-95.
29. DementiaGuide. 2015 [cited June 9, 2015]. Available from: http://www.dementiaguide.com/symptomlibrary/memorylanguage/language_difficulty/managementstrategies/. Accessed April 20, 2015.
30. Zemek F, Drtinova L, Nepovimova E, et al. Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine. Expert Opin Drug Saf. 2014;13(6):759-774.
31. Nepovimova E, Uliassi E, Korabecny J, et al. Multitarget drug design strategy: quinone-tacrine hybrids designed to block amyloid-β aggregation and to exert anticholinesterase and antioxidant effects. J Med Chem. 2014;57(20):8576-8589.
32. Hilari K, Needle JJ, Harrison KL. What are the important factors in health-related quality of life for people with aphasia? A systematic review. Arch Phys Med Rehabil. 2012;93(suppl 1):86-95.
33. Ferris S, Ihl R, Robert P, et al. Treatment effects of memantine on language in moderate to severe Alzheimer's disease patients. Alzheimers Dement. 2009;5:369-374.
34. Winblad B, Kilander L, Eriksson S, et al; Severe Alzheimer's Disease Study Group. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet. 2006;367(9516):1057-1065.
35. Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology. 2007;69(5):459-469.
36. Cummings J, Jones R, Wilkinson D, et al. Effect of donepezil on cognition in severe Alzheimer's disease: a pooled data analysis. J Alzheimers Dis. 2010;21(3):843-851.
37. Winblad B, Black SE, Homma A, et al. Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials. Curr Med Res Opin. 2009;25(11):2577-2587.
38. Schwam E, Xu Y. Cognition and function in Alzheimer's disease: identifying the transitions from moderate to severe disease. Dement Geriatr Cogn Disord. 2010;29(4):309-316.
39. Ferris SH, Schmitt FA, Saxton J, et al. Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease. Alzheimers Res Ther. 2011;3(3):22.
40. Farlow MR, Cummings JL, Olin JT, Meng X. Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2010;25(4):347-352.
41. Grossberg GT, Schmitt FA, Meng X, Tekin S, Olin J. Reviews: effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2010;25(8):627-633.
42. Burns A, Bernabei R, Bullock R, et al. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial. Lancet Neurol. 2009;8(1):39.
43. Clare L, Woods R. Cognitive rehabilitation in dementia. Neuropsychol Rehabil. 2001;11:193-517.
44. Zientz J, Rackley A, Chapman SB, et al. Evidence-based practice recommendations for dementia: educating caregivers on Alzheimer's disease and training communication strategies. J Med Speech Lang Pathol. 2007;15(1):liii-lxiv.
45. Drug Treatment for Alzheimer's Disease; 2015 [cited June 9, 2015]. Available from: http://www.alzheimers.org.uk/site/scripts/documents_info.php?documentID=147. Accessed April 20, 2015.
46. Mayo Clinic Staff. Alzheimer's: Drugs Help Manage Symptoms; 2014 [cited June 9, 2015]. Available from: http://www.mayoclinic.org/diseases-conditions/alzheimers-disease/in-depth/a%20lzheimers/art-20048103. Accessed April 20, 2015.
47. Pope SK, Shue VM, Beck C. Will a healthy lifestyle help prevent Alzheimer's disease. Annu Rev Public Health. 2003;24:111-132.
48. Kivipelto M, Solomon A. Alzheimer's disease - the ways of prevention. J Nutr Health Aging. 2007;12:89-94.
49. Radak Z, Hart N, Sarga L, et al. Exercise plays a preventive role against Alzheimer's disease. J Alzheimers Dis. 2010;20:777-783.
50. Rovio S, Kåreholt I, Helkala EL, et al. Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. Lancet Neurol. 2005;4:705-711.
51. Joe Verghese MD, Richard B, Lipton MD. Leisure Activities and the risk of dementia in the elderly. N Engl J Med. 2003;348:2508-2516.
52. Craik FIM, Bialystock E, Freedman M. Delaying the onset of Alzheimer's disease. Bilingualism as a form of cognitive reserve. Neurology. 2010;75(19):1726-1729.
53. Bialystok E, Craik FIM, Luk G. Bilingualism: consequences for mind and brain. Trends Cogn Sci. 2012;16(4):240-250.
54. Bialystok E, Craik FIM, Freedman M. Bilingualism as a protection against the onset of symptoms of dementia. Neuropsychologia. 2007;45:459-464.
55. Soares FC, de Oliveira TC, de Macedo LD, et al. CANTAB object recognition and language tests to detect aging cognitive decline: an exploratory comparative study. Clin Interv Aging. 2015;10:37-48.
56. Vestal L, Smith-Olinde L, Hicks G, Hutton T, Hart J Jr. Efficacy of language assessment in Alzheimer's disease: comparing in-person examination and telemedicine. Clin Interv Aging. 2006;1(4):467-471.
57. Sköldunger A, Johnell K, Winblad B, Wimo A. Mortality and treatment costs have a great impact on the cost-effectiveness of disease modifying treatment in Alzheimer's disease - a simulation study. Curr Alzheimer Res. 2013;10:207-216.
58. Soukup O, Jun D, Zdarova-Karasova J, et al. A resurrection of 7-MEOTA: a comparison with tacrine. Curr Alzheimer Res. 2013;10(8):893-906.